Volume : 13, Issue : 03, March – 2026
Title:
NANOPARTICLE-BASED DRUG DELIVERY AND DRUG REPURPOSING STRATEGIES FOR PARKINSON’S DISEASE: OVERCOMING BLOOD–BRAIN BARRIER CHALLENGES
Authors :
Diksha R. Bhalerao,Sapna K. Dandekar, Mr. Rahul G. Arote
Abstract :
Parkinson’s Disease is considered as a neurodegenerative disorder and is identified by the deterioration of the motor functions due to loss of the dopamine releasing neurons. Due to this dementia occurs which is characterised by forgetfulness and impairment in cognitive abilities. The effectiveness, cellular penetration and transport of drugs to the target organs, tissues or cells is the main hindrance in the diagnosis and the treatment of this disorder. The main obstacle in the drug delivery system is the presence of blood brain barrier which checks the penetration of drugs and causes side effects. Nanoparticle eases the drug delivery to the central nervous system via blood brain barrier against the conventional drug delivery.
Parkinson’s disease (PD) significantly affects patients quality of life and represents a high economic burden for health systems. Given the lack of safe and effective treatments for PD, drug repositioning seeks to offer new medication alternatives, reducing research time and costs compared to the traditional drug development strategy. This review aimed to collect evidence of drugs proposed as candidates to be reused in PD and identify those with the potential to be reformulated into nanocarriers to optimize future repositioning trials. We conducted a detailed search in PubMed, Web of Science, and Scopus from January 2015 at the end of 2021, with the descriptors “Parkinson’s disease” and “drug repositioning” or “drug repurposing”.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopa minergic neurons in the substantia nigra, resulting in dopamine deficiency and motor dysfunction. While levodopa (L- DOPA) re mains the gold standard for symptomatic treatment, its long- term administration is associated with complications such as motor fluctuations, dyskinesia, and oxidative stress. Given these limitations, interest has grown in plant- derived bioactive compounds for their potential neuroprotective and disease- modifying effects.
KEYWORDS: Neurodegenerative disorder, Blood Brain Barrier, Nanoparticles, Nanotechnology. Drug repositioning, Drug repurposing, Parkinson’s disease, Nanoparticles, Nanocarriers, Pharmaceutical nanotechnology
Cite This Article:
Please cite this article in press Diksha R. Bhalerao et al., Nanoparticle-Based Drug Delivery And Drug Repurposing Strategies For Parkinson’s Disease: Overcoming Blood–Brain Barrier Challenges., Indo Am. J. P. Sci, 2026; 13(03).
REFERENCES:
1. Zhang Q, Wang Q, Fu J, Xu X, Guo D, Pan Y, et al. Multi targeted therapy for Alzheimer’s disease by guanidinium-modified calixarene and cyclodextrin co-assembly loaded with insulin. ACS Nano. (2024) 18:33032–41. doi: 10.1021/acsnano.4c05693
2. Duan W, Yang L, Liu J, Dai Z, Wang Z, Zhang H, et al. A TGF-β signalling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response. CNS Neurosis Ther. (2024) 30:e14489. doi: 10.1111/cns.14489
3. Zhang C, Ge H, Zhang S, Liu D, Jiang Z, Lan C, et al. Hematoma evacuation via image-guided para-corticospinal tract approach in patients with spontaneous intracerebral haemorrhage. Neurula Ther. (2021) 10:1001–13. doi: 10.1007/s40120-021-00279-8
4. Benedetti F, Bernasconi A, Pontiggia A. Depression and neurological disorders. Curr Opin Psychiatry. (2006) 19:14–8. doi: 10.1097/01.yco.0000194147.88647.7f
5. Wang L, Li X, Deng Z, Cai Q, Lei P, Xu H, et al. Neuroendoscopic Para fascicular evacuation of spontaneous intracerebral haemorrhage (NESICH technique): a multicentre technical experience with preliminary findings. Neurula Ther. (2024) 13:1259–71. doi: 10.1007/s40120-024-00642-5
6. Wang H, Yan Z, Yang W, Liu R, Fan G, Gu Z, et al. A strategy of monitoring acetylcholinesterase and screening of natural inhibitors from Unscarier for Alzheimer’s disease therapy based on near-infrared fluorescence probe. Sens Actuators B. (2025) 424:136895. doi: 10.1016/j.snb.2024.136895
7. Griswold W. The expanding burden of neurological disorders. Lancet Neurol. (2024) 23:326–7. doi: 10.1016/S1474-4422(24)00086-3
8. Powe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. (2017) 3:17013. doi: 10.1038/nrdp.2017.13
9. Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. (2021) 7:47. doi:
10.1038/s41572-021-00280-3 10. Muleiro Alvarez M, Cano-Herrera G, Osorio Martínez MF, Vega Gonzales-Portillo J, Monroy GR, Murguiondo Pérez R, et al. A comprehensive approach to Parkinson’s disease: addressing its molecular, clinical, and therapeutic aspects. Int J Mol Sci. (2024) 25:7183. doi: 10.3390/ijms25137183
11. Pardo-Moreno T, García-Morales V, Suleiman-Martos S, Rivas-Domínguez A, Mohamed-Mohamed H, Ramos-Rodríguez JJ, et al. Current treatments and new, tentative therapies for Parkinson’s disease. Pharmaceutics. (2023) 15:770. doi: 10.3390/ pharmaceutics15030770
12 . Ali, I., Adil, M., Imran, M., Qureshi, S.A., Qureshi, S. and Hasan, N., 2026. Nanotechnology in Parkinson’s disease: overcoming drug delivery challenges and enhancing therapeutic outcomes. Drug Delivery and Translational Research, 16(3), pp.855–893.
13. Saraswathi, T.S., Mothilal, M., Bukke, S.P.N., Thalluri, C. and Chettupalli, A.K., 2025. Recent advances in potential drug nanocarriers for CNS disorders: a review. BioMedical Engineering OnLine, 24, p.137.
14 . Senanayake, D., Yapa, P., Dabare, S. and Munaweera, I., 2025. Precision targeting of the CNS: recent progress in brain-directed nanodrug delivery. RSC Advances, 15, pp.25910–25928.
14. Sathasivan, S., Annamalai, J., Bathcha, S.K.S. and Annamalai, J., 2025. Nanotechnology-based drug delivery and marine diet derived compounds in alpha-synuclein-linked Parkinson’s disease. Junior Researchers, 3(2).
15. Currie, A.D., Wong, J.K. and Okun, M.S., 2024. A review of temporal interference, nanoparticles, ultrasound, gene therapy, and designer receptors for Parkinson disease. npj Parkinson’s Disease, 10, p.195.
16 . Virameteekul, S., Lees, A.J. and Bhidayasiri, R., 2024. Small particles, big potential: polymeric nanoparticles for drug delivery in Parkinson’s disease. Movement Disorders, 39(11), pp.1922–1937.
17. Derman, S., Yergök, R.A., Alakbarli, J. and Eskhita, A.S., 2024. Brain-targeted nano-drug delivery for the treatment of Parkinson’s disease. Current Research in Health Sciences, 1(2), pp.77–92.
18 .Pranay, R., Tatikayala, R.K., Damera, S., Pathakala, N. and Jadi, R.K., 2024. Insights of nose-to-brain delivery in treating Parkinson’s disease: a systematic review. Journal of Applied Pharmaceutical Research, 12(6), pp.57–72.
19 . Prema, R., Prabhakaran, M., Meenakshi, M. and Sankar, C., 2025. A comprehensive review on nanostructured lipid carriers. Journal of Drug Delivery and Therapeutics, 15(10), pp.172–186.
20. Baskin, J., Jeon, J.E. and Lewis, S.J.G., 2021. Nanoparticles for drug delivery in Parkinson’s disease. Journal of Neurology, 268(5), pp.1981–1994.